PORT ST. LUCIE, FL, Apr 02, 2012 (otcenews.com) — Water Technologies International, Inc. (PINKSHEETS: WTII) announced today that it has received an initial purchase order from Atmospheric Water Systems, Inc. for 1,000 home and office units. In addition, Atmospheric Water Systems has indicated an interest in purchasing an additional 25,000 units. Atmospheric Water Systems is a California company that has been in the AWG business for the past four years. It will sell GR8 Water AWGs under a private licensing and distribution agreement. The manufacturer’s suggested retail price is now $1,995. The wholesale price will be based on the purchase order quantity and the yearly volume of the distributor.

The Company’s atmospheric water generators (AWG), which produce an average of seven gallons of pure drinking water per day, can now be purchased, leased or rented under 100% financing terms for qualified buyers. For a home or office unit, this equates to approximately $55 per month on a 48 month term and equates to less than $2 per day. GR8 Water will offer the 100% financing option to the U.S. distributors for individuals or businesses on single unit or multiple unit purchases. Read more »

HOUSTON, TX, Apr 02, 2012 (otcenews.com) — Planet Resource Recovery, Inc. (PINKSHEETS: PRRY) and Kent Weisenberg are pleased to announce that they have entered into a Settlement Agreement and Mutual Release, effective March 8, 2012, fully and finally resolving all disputes between all parties. By virtue of that Agreement, all parties have fully released one another and dismissed all lawsuits, 17,964,285 shares of restricted PRRY common stock issued in connection with the underlying transaction have been returned to Planet, and all intellectual property acquired from Weisenberg by Planet has been returned to Weisenberg. All other terms of the Agreement remain confidential. Read more »

LA MIRADA, CA, Mar 26, 2012 (otcenews.com) — BioLargo, Inc. (OTCBB: BLGO), creator of patented iodine technologies, today announced the development of recent commercial opportunities and that its work to solve the contaminated water issues associated with the Canadian Oil Sands, as a founding member of a NSERC Canadian Research Chair at the University of Alberta Department of Engineering, has begun.

BioLargo announced the introduction of its free iodine liquid wash and “hydrogel” products branded Nature’s Best Solution(R). The wash and hydrogel have both consumer and industrial strength applications for use as a general wash and odor control. The company generated its first commercial sale and has begun to deliver the products to prospective industrial customers for trials. They deliver the market’s highest dose of free iodine in solution while retaining its non-staining, G.R.A.S. (Generally Regarded as Safe) designation, as well as its non-toxic and green attributes. Slated to become a staple in BioLargo’s product menu, the stabilized formula provides a platform for new products because additional ingredients can easily be added to create a host of new applications. BioLargo will continue to validate the base product and secure commercial opportunities while it seeks to establish a distribution channel. Read more »

MONTREAL, Mar 26, 2012 (otcenews.com) — Sunshine Biopharma, Inc. (OTCBB: SBFM), which has designed and synthesized a new compound, Adva-27a, that acts as an inhibitor of multidrug resistant breast cancer cells in vitro, today announced that it will be presenting new scientific data at the American Association for Cancer Research Meeting March 31-April 4, 2012, in Chicago, Illinois, together with its research collaborator, Binghamton University, a State University of New York.

According to the American Cancer Society, approximately 1.5 million new cases of cancer are diagnosed each year in the U.S. Of these, over 230,000 are new breast cancer cases. The American Cancer Society also reports that there are over 11 million Americans living with cancer. Of these, 2.5 million are breast cancer patients. Virtually all cancers types are either aggressive at the onset or become aggressive or multidrug resistant over time. Currently, there are little or no treatment options available for multidrug resistant breast cancer patients. Read more »